Baseline PSA as a predictor of prostate cancer-specific mortality
July 24th, 2010 Posted in prostate cancer risksA new study at Duke University Medical Center, Durham, North Carolina, investigated the possibility of identification of the risk of death from prostate cancer and death from all causes using information available at the time of baseline prostate-specific antigen (PSA) measurement.
Researchers concluded Baseline PSA measurement appears to be particularly pertinent and a reliable and independent predictor of death from prostate cancer. A baseline PSA of 4 ng/mL has been associated with higher risk of death from prostate cancer.